Covered recipient · General Payments record
BETH D REID
Allopathic & Osteopathic Physicians Obstetrics & Gynecology
General Payments · PY2018–2024
$2,112.29
- Reported across 105 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $226.26 | 15 |
| Education | $80.10 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| MILLICENT US INC | $99.04 | 2 |
| MAYNE PHARMA COMMERCIAL LLC | $54.77 | 3 |
| Sumitomo Pharma America, Inc. | $54.76 | 3 |
| Organon LLC | $40.01 | 4 |
| Exeltis, USA Inc. | $16.77 | 1 |
| MIMEDX Group, Inc. | $15.92 | 1 |
| PFIZER INC. | $14.55 | 1 |
| Aspira Women's Health Inc | $10.54 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Aspira Women's Health Inc | $10.54 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126779282 | CMS |
| Exeltis, USA Inc. | $16.77 | 09/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150002810 | CMS |
| MAYNE PHARMA COMMERCIAL LLC | $15.34 | 05/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154682589 | CMS |
| MAYNE PHARMA COMMERCIAL LLC | $20.38 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154682593 | CMS |
| MAYNE PHARMA COMMERCIAL LLC | $19.05 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154682591 | CMS |
| MILLICENT US INC | $80.10 | 10/11/2024 | Education | Undisputed | 01/23/2026 | 1150911294 | CMS |
| MILLICENT US INC | $18.94 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150911296 | CMS |
| MIMEDX Group, Inc. | $15.92 | 10/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140267991 | CMS |
| Organon Llc | $12.67 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136256053 | CMS |
| Organon Llc | $20.85 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136256057 | CMS |
| Organon Llc | $0.31 | 09/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136256061 | CMS |
| Organon Llc | $6.18 | 09/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136256065 | CMS |
| PFIZER INC. | $14.55 | 03/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131012511 | CMS |
| Sumitomo Pharma America, Inc. | $18.34 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148908938 | CMS |
| Sumitomo Pharma America, Inc. | $17.71 | 08/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148908940 | CMS |
| Sumitomo Pharma America, Inc. | $18.71 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148908942 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.